Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has released its financial results for the year ended December 31, 2025, alongside significant business updates. The company reported cash, cash equivalents, and marketable securities totaling $116.9 million as of December 31, 2025, which is expected to support its clinical and operational activities into early 2027. Acumen is advancing its lead therapeutic candidate, sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). The company anticipates topline results from its Phase 2 ALTITUDE-AD study, which investigates sabirnetug for early AD, to be reported in late 2026. This study has fully enrolled 542 participants across multiple countries, including the U.S., Canada, and the U.K. The company also announced a recent $35.75 million private placement to further its Enhanced Brain Delivery (EBD) program, which aims to develop oligomer-targeted antibodies with blood-brain barrier-penetrating technology. The financial results indicate an increase in research and development expenses to $104.9 million for 2025, up from $93.8 million in 2024, primarily due to costs associated with the ALTITUDE-AD clinical trial. Acumen's net loss for the year was reported at $121.3 million, compared to $102.3 million in the previous year. The company continues to focus on delivering innovative treatment options for Alzheimer’s patients, with a strong emphasis on scientific innovation and execution.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.